Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis

[EN]Previous studies have suggested that the effect of naltrexone in patients with alcohol dependence may be moderated by genetic factors. In particular, the possession of the G allele of the A118G polymorphism of the m-opioid receptor gene (OPRM1) has been associated with a better response to naltr...

Descripción completa

Detalles Bibliográficos
Autores: Chamorro Fernández, Antonio Javier, Marcos Martín, Miguel, Mirón Canelo, José Antonio, Pastor Encinas, Isabel, González Sarmiento, Rogelio, Laso Guzmán, Francisco Javier
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2012
País:España
Institución:Universidad de Salamanca (USAL)
Repositorio:GREDOS. Repositorio Institucional de la Universidad de Salamanca
OAI Identifier:oai:gredos.usal.es:10366/154043
Acceso en línea:http://hdl.handle.net/10366/154043
Access Level:acceso abierto
Palabra clave:Alcoholism
Drug therapy
Genetics
Meta-analysis
Naltrexone
Therapeutic use
Pharmacogenetics
Opioid mu receptors
Systematic review
Receptors, Opioid, mu
Meta-Analysis
Therapeutic Uses
Drug Therapy
alcoholismo
farmacogenética
naltrexona
usos terapéuticos
metanálisis
genética
farmacoterapia
receptores opioides mu
id ES_41f4e4d950432a0dceb3261f3f234d7c
oai_identifier_str oai:gredos.usal.es:10366/154043
network_acronym_str ES
network_name_str España
repository_id_str
spelling Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysisChamorro Fernández, Antonio JavierMarcos Martín, MiguelMirón Canelo, José AntonioPastor Encinas, IsabelGonzález Sarmiento, RogelioLaso Guzmán, Francisco JavierAlcoholismDrug therapyGeneticsMeta-analysisNaltrexoneTherapeutic usePharmacogeneticsOpioid mu receptorsSystematic reviewPharmacogeneticsReceptors, Opioid, muGeneticsMeta-AnalysisAlcoholismNaltrexoneTherapeutic UsesDrug Therapyalcoholismofarmacogenéticanaltrexonausos terapéuticosmetanálisisgenéticafarmacoterapiareceptores opioides mu[EN]Previous studies have suggested that the effect of naltrexone in patients with alcohol dependence may be moderated by genetic factors. In particular, the possession of the G allele of the A118G polymorphism of the m-opioid receptor gene (OPRM1) has been associated with a better response to naltrexone, although controversial results have been reported. The aim of this paper is to combine previous findings by means of a systematic review and a meta-analysis. We retrieved studies on the relationship between A118G polymorphism in OPRM1 gene and response to treatment with naltrexone in patients with alcohol dependence by means of electronic database search. A meta-analysis was conducted using a random-effects model. Calculations of odds ratio (OR) and their confidence intervals (CI) and tests for heterogeneity of the results have been performed. Six previous studies have analyzed the role of A118G polymorphism in response to naltrexone for alcohol dependence. After meta-analysis, we found that naltrexone-treated patients carrying the G allele had lower relapse rates than those who were homozygous for the A allele (OR: 2.02, 95% CI 1.26–3.22; P = 0.003). There were no differences in abstinence rates. Our results support the fact that the G allele of A118G polymorphism of OPRM1 moderates the effect of naltrexone in patients with alcohol dependence. This genetic marker may therefore identify a subgroup of individuals more likely to respond to this treatment.Wiley202420242012info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10366/154043reponame:GREDOS. Repositorio Institucional de la Universidad de Salamancainstname:Universidad de Salamanca (USAL)InglésAttribution-4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:gredos.usal.es:10366/1540432026-06-07T06:28:51Z
dc.title.none.fl_str_mv Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis
title Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis
spellingShingle Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis
Chamorro Fernández, Antonio Javier
Alcoholism
Drug therapy
Genetics
Meta-analysis
Naltrexone
Therapeutic use
Pharmacogenetics
Opioid mu receptors
Systematic review
Pharmacogenetics
Receptors, Opioid, mu
Genetics
Meta-Analysis
Alcoholism
Naltrexone
Therapeutic Uses
Drug Therapy
alcoholismo
farmacogenética
naltrexona
usos terapéuticos
metanálisis
genética
farmacoterapia
receptores opioides mu
title_short Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis
title_full Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis
title_fullStr Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis
title_full_unstemmed Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis
title_sort Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis
dc.creator.none.fl_str_mv Chamorro Fernández, Antonio Javier
Marcos Martín, Miguel
Mirón Canelo, José Antonio
Pastor Encinas, Isabel
González Sarmiento, Rogelio
Laso Guzmán, Francisco Javier
author Chamorro Fernández, Antonio Javier
author_facet Chamorro Fernández, Antonio Javier
Marcos Martín, Miguel
Mirón Canelo, José Antonio
Pastor Encinas, Isabel
González Sarmiento, Rogelio
Laso Guzmán, Francisco Javier
author_role author
author2 Marcos Martín, Miguel
Mirón Canelo, José Antonio
Pastor Encinas, Isabel
González Sarmiento, Rogelio
Laso Guzmán, Francisco Javier
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Alcoholism
Drug therapy
Genetics
Meta-analysis
Naltrexone
Therapeutic use
Pharmacogenetics
Opioid mu receptors
Systematic review
Pharmacogenetics
Receptors, Opioid, mu
Genetics
Meta-Analysis
Alcoholism
Naltrexone
Therapeutic Uses
Drug Therapy
alcoholismo
farmacogenética
naltrexona
usos terapéuticos
metanálisis
genética
farmacoterapia
receptores opioides mu
topic Alcoholism
Drug therapy
Genetics
Meta-analysis
Naltrexone
Therapeutic use
Pharmacogenetics
Opioid mu receptors
Systematic review
Pharmacogenetics
Receptors, Opioid, mu
Genetics
Meta-Analysis
Alcoholism
Naltrexone
Therapeutic Uses
Drug Therapy
alcoholismo
farmacogenética
naltrexona
usos terapéuticos
metanálisis
genética
farmacoterapia
receptores opioides mu
description [EN]Previous studies have suggested that the effect of naltrexone in patients with alcohol dependence may be moderated by genetic factors. In particular, the possession of the G allele of the A118G polymorphism of the m-opioid receptor gene (OPRM1) has been associated with a better response to naltrexone, although controversial results have been reported. The aim of this paper is to combine previous findings by means of a systematic review and a meta-analysis. We retrieved studies on the relationship between A118G polymorphism in OPRM1 gene and response to treatment with naltrexone in patients with alcohol dependence by means of electronic database search. A meta-analysis was conducted using a random-effects model. Calculations of odds ratio (OR) and their confidence intervals (CI) and tests for heterogeneity of the results have been performed. Six previous studies have analyzed the role of A118G polymorphism in response to naltrexone for alcohol dependence. After meta-analysis, we found that naltrexone-treated patients carrying the G allele had lower relapse rates than those who were homozygous for the A allele (OR: 2.02, 95% CI 1.26–3.22; P = 0.003). There were no differences in abstinence rates. Our results support the fact that the G allele of A118G polymorphism of OPRM1 moderates the effect of naltrexone in patients with alcohol dependence. This genetic marker may therefore identify a subgroup of individuals more likely to respond to this treatment.
publishDate 2012
dc.date.none.fl_str_mv 2012
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10366/154043
url http://hdl.handle.net/10366/154043
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv Attribution-4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:GREDOS. Repositorio Institucional de la Universidad de Salamanca
instname:Universidad de Salamanca (USAL)
instname_str Universidad de Salamanca (USAL)
reponame_str GREDOS. Repositorio Institucional de la Universidad de Salamanca
collection GREDOS. Repositorio Institucional de la Universidad de Salamanca
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406890388094977
score 15,300719

Similares en LA Referencia